SAN DIEGO - AstraZeneca (NASDAQ:AZN) is set to present new clinical and real-world data on its respiratory and immune-mediated disease treatments at the upcoming American Thoracic Society (ATS) International Conference, which takes place from May 17 to May 22, 2024, in San Diego, California.
The pharmaceutical company announced today that it will showcase 59 abstracts, including 12 late-breaking posters, highlighting its comprehensive inhaled and biologic therapies, as well as advancements in early science.
The research focuses on addressing unmet needs in several chronic respiratory conditions, such as chronic obstructive pulmonary disease (COPD), severe asthma, and eosinophilic granulomatosis with polyangiitis (EGPA). These diseases represent a significant burden for patients, and AstraZeneca aims to demonstrate the strength and depth of its portfolio in these therapeutic areas.
AstraZeneca's presentations at the ATS conference will cover a range of topics, from the efficacy and safety of existing treatments to new findings that could inform future therapies. The company's commitment to advancing respiratory medicine is underscored by the breadth of data it will share with the medical community.
The ATS conference is a globally recognized gathering of healthcare professionals and researchers specializing in pulmonary, critical care, and sleep medicine. It provides a platform for the latest innovations in research, clinical care, and treatment of respiratory diseases.
This announcement is based on a press release statement and aims to provide an overview of AstraZeneca's participation in the ATS 2024 conference. The company's research endeavors are part of its ongoing efforts to improve patient outcomes and address the challenges posed by respiratory and immune-mediated diseases.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.